AIM ImmunoTech Inc (AIM) Shares Decline Despite Market Challenges

7h ago, source: newsheater

The net margin for AIM ImmunoTech Inc stands at -139.35. The total capital return value is set at -2.93. Equity return is now at value -118.94, with -64.84 for asset returns.

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

1d ago, source:

Charles W. Lapp, MD Charles W. Lapp, MD OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM”) today ...

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

5d ago, source:

OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO ...

AIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcript

13d ago, source: Insider Monkey

AIM ImmunoTech Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the ...

AIM ImmunoTech Inc.

10d ago, source: CNN

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders.

Aim ImmunoTech Announces Positive Data From Ampligen Study In Combination With Pembrolizumab

6d ago, source:

Aim ImmunoTech Inc. (AIM) announced positive preliminary findings on Wednesday, showing that pairing Ampligen or rintatolimod with ...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

14d ago, source: Business Insider

April 02, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the full year 2023 and provided a business update.

AIM ImmunoTech Inc

22d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AIM ImmunoTech Inc.: AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

1d ago, source:

AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen ...

AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript

14d ago, source: Seeking Alpha

Hello. And welcome to the AIM ImmunoTech Fiscal Year 2023 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode. [Operator Instructions ...